title: Effect of opioid substitution therapy on alcohol metabolism.
abstract: Forty opioid substitution patients (methadone, n = 14; LAAM, n = 14; and buprenorphine, n = 12) who were participating in a study on the impact of opiate substitution treatment on driving ability and 22 non-opiate-using control subjects were administered 14.7 g/70 kg of alcohol in two separate sessions, one 2-3 hours before opioid pharmacotherapy dosing and the other 1-2 hours after dosing. The mean blood alcohol concentration (BAC) in the post-opioid dose session was significantly lower than that in the pre-opioid dose session (p < .05). There was a significant effect of experimental group (LAAM, methadone, buprenorphine, or control) on BAC in sessions conducted 1-2 hours after the opioid substitution dose (p < .01). There was a trend for a reduced effect of experimental group on BAC in the pre-opioid substitution dose session (p = .06). The BAC of non-opioid substitution control subjects was significantly higher than that of the LAAM (before and after LAAM dosing) and methadone (after methadone dosing; p < .05) patients. These findings provide evidence for the first time of an interaction between opiates and alcohol in humans that is strongest at the time of peak opiate plasma levels in the hours after opioid dosing.
authors.affiliation: Turning Point Alcohol and Drug Center Inc., Victoria, Australia. nico.clark@turningpoint.org.au
authors.forename: Nicolas C
authors.initials: NC
authors.lastname: Clark
authors.forename: Paul
authors.initials: P
authors.lastname: Dietze
authors.forename: Michael G
authors.initials: MG
authors.lastname: Lenné
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Redman
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D002047:Buprenorphine / Q000009:adverse effects* / Q000627:therapeutic use; D002492:Central Nervous System Depressants / Q000097:blood / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D000431:Ethanol / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000009:adverse effects* / Q000627:therapeutic use; D008692:Methadyl Acetate / Q000009:adverse effects* / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000534:rehabilitation*
chemical_list: D000701:Analgesics, Opioid; D002492:Central Nervous System Depressants; D000431:Ethanol; D002047:Buprenorphine; D008692:Methadyl Acetate; D008691:Methadone